Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2026 · 10-Q
Revenue$20.50M$20.50M−29.8% vs Q2 2025 Net Income-$703.00K-$703.00KN/M vs Q2 2025 EPS Diluted-$0.04-$0.04N/M vs Q2 2025 Operating Income-$88,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$8,576,000+88.4% Margins · derivedOperating margin-0.4%−11.4 pt vs Q2 2025
Net margin-3.4%−8.7 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end